Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Imaging And Path Lab's Days Sales Outstanding for the
six
months ended in Mar. 2026 was 256.41.
Star Imaging And Path Lab's Days Inventory for the
six
months ended in Mar. 2026 was 2.7.
Star Imaging And Path Lab's Days Payable for the
six
months ended in Mar. 2026 was 92.84.
Therefore, Star Imaging And Path Lab's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2026 was 166.27.
Star Imaging And Path Lab (BOM:544482) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Star Imaging And Path Lab Cash Conversion Cycle Related Terms
Star Imaging And Path Lab Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Imaging And Path Lab Cash Conversion Cycle Chart
BOM:544482 vs TMO, DHR, IDXX: Cash Conversion Cycle Comparison
For the Diagnostics & Research subindustry, Star Imaging And Path Lab's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Imaging And Path Lab Cash Conversion Cycle vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Star Imaging And Path Lab's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Star Imaging And Path Lab's Cash Conversion Cycle falls into.
Star Imaging And Path Lab Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Star Imaging And Path Lab's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Imaging And Path Lab (BOM:544482) has a Cash Conversion Cycle of 166.27 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Star Imaging And Path Lab and its competitors.
Is Star Imaging And Path Lab's Cash Conversion Cycle too high?
Star Imaging And Path Lab's current Cash Conversion Cycle is 166.27. The Medical Diagnostics & Research industry median Cash Conversion Cycle is 72.23. Star Imaging And Path Lab's value of 166.27 is 130.2% above this industry median. Overall, Star Imaging And Path Lab has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Star Imaging And Path Lab's Cash Conversion Cycle compare to TMO and DHR?
Star Imaging And Path Lab's Cash Conversion Cycle of 166.27 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Cash Conversion Cycle is 72.23. Star Imaging And Path Lab's value of 166.27 is 130.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Diagnostics & Research company?
The median Cash Conversion Cycle among Medical Diagnostics & Research companies is 72.23, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Imaging And Path Lab's current Cash Conversion Cycle of 166.27 is 130.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Star Imaging And Path Lab and its competitors. For the Medical Diagnostics & Research industry, the median Cash Conversion Cycle is 72.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Imaging And Path Lab's current Cash Conversion Cycle is 166.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Imaging And Path Lab stock overvalued right now?
Star Imaging And Path Lab (BOM:544482) has a current Cash Conversion Cycle of 166.27. The current Cash Conversion Cycle is 166.27 and 130.2% above the Medical Diagnostics & Research industry median of 72.23. Star Imaging And Path Lab's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Star Imaging And Path Lab (BOM:544482), the current Cash Conversion Cycle is 166.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Star Imaging And Path Lab Ltd operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi and Uttar Pradesh. It offers a comprehensive range of diagnostic imaging services and clinical laboratory tests, including both routine and specialized studies and profiles. These services are essential for the prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. The company's diagnostic imaging and radiology services encompass X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, ultrasounds, bone mineral densitometry, and mammography.
21GF Score
Get the complete analysis for BOM:544482
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544482 has been successfully added to your 
